Human Laboratory Screening of Semaglutide for Alcohol Use Disorder

项目总结 药物治疗的发展仍然是减少相关的健康和社会负担的关键目标 患有酒精使用障碍(AUD)。为特定的AUD亚群开发有针对性的治疗是一个关键目标 根据NIAAA的药物发展战略。在患有澳元的人中，吸烟者包括 长期健康风险高得不成比例的规模和关键亚群，使其成为关键优先事项 并发AUD和吸烟的高级治疗。最近的临床前证据表明 胰高血糖素型多肽-1是一种内分泌激素，影响酒精的动机和摄入量。到目前为止，还没有研究表明 GLP-1受体药物对人类酒精动机和奖赏影响的研究进展 参与者。人体实验室药物试验为临床前验证提供了一个既省时又省钱的选择 在进行更大规模的随机对照试验之前的研究结果。该项目将利用人体实验室 评价GLP-1受体激动剂作为治疗吸烟者的新候选疗法的筛选程序 澳元。符合AUD标准并报告经常轻度至中度吸烟的参与者将完成 受试者内的酒精给药程序，平衡设计。这项研究将提供初步的 GLP-1受体激动剂对酒精相关结局影响的人体数据，包括两者 酒精和尼古丁的动机，在患有AUD的参与者中。一种候选关节单一疗法的有效性验证 酒精和尼古丁的减少可能会对公众健康产生重大影响。

PROJECT SUMMARY Pharmacotherapy development remains a critical objective for reducing health and societal burdens associated with alcohol use disorder (AUD). Developing targeted treatments for specific AUD subgroups is a key aim under the NIAAA medication development strategy. Among those with AUD, cigarette smokers comprise a sizable and critical subgroup with disproportionally high long-term health risks, making it a key priority to advance therapies for concurrent AUD and cigarette smoking. Recent preclinical evidence indicates that glucagon-type peptide-1, an incretin hormone, impacts alcohol motivation and intake. So far, no studies have reported on the effects of GLP-1 receptor medications on aspects of alcohol motivation and reward in human participants. Human laboratory medication trials offer a time- and cost-effective option for validating preclinical findings prior to carrying out larger randomized controlled trials. This project will utilize human laboratory screening procedures to evaluate a GLP-1 receptor agonist as a novel candidate therapy for smokers with AUD. Participants who meet criteria for AUD and report regular light-to-moderate smoking will complete alcohol administration procedures in a within-subjects, counter-balanced design. This study will provide initial human data on the effects of a GLP-1 receptor agonist in relation to alcohol-related outcomes, including both alcohol and nicotine motivation, in participants with AUD. Validation of a candidate monotherapy for joint alcohol and nicotine reduction could have substantial public health impact.